Article Figures & Data
Figures
- Figure 1.
Progression-Free Survival in the DECISION Trial of Sorafenib vs Placebo
Reprinted from Lancet, 384, Brose MS et al, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomized, double-blind, phase 3 trial, 384:319-328, Copyright (2014), with permission from Elsevier.
Tools
Targeted and Salvage Therapies Benefit Patients With Thyroid Cancer
Permalink:
Table of contents
Cited By...
- No citing articles found.